146 related articles for article (PubMed ID: 35178362)
1. Plasma Chemokine C-C Motif Ligand 2 as a Potential Biomarker for Prostate Cancer.
Lund M; Pedersen TB; Feddersen S; Østergaard LD; Poulsen CA; Enggaard C; Poulsen MHA; Lund L
Res Rep Urol; 2022; 14():33-38. PubMed ID: 35178362
[TBL] [Abstract][Full Text] [Related]
2. Serum CCL2 Is a Prognostic Biomarker for Non-Metastatic Castration-Sensitive Prostate Cancer.
Iwamoto H; Izumi K; Nakagawa R; Toriumi R; Aoyama S; Kamijima T; Shimada T; Kano H; Makino T; Naito R; Kadomoto S; Yaegashi H; Kawaguchi S; Nohara T; Shigehara K; Kadono Y; Mizokami A
Biomedicines; 2022 Sep; 10(10):. PubMed ID: 36289628
[TBL] [Abstract][Full Text] [Related]
3. Serum chemokine (CC motif) ligand 2 level as a diagnostic, predictive, and prognostic biomarker for prostate cancer.
Izumi K; Mizokami A; Lin HP; Ho HM; Iwamoto H; Maolake A; Natsagdorj A; Kitagawa Y; Kadono Y; Miyamoto H; Huang CK; Namiki M; Lin WJ
Oncotarget; 2016 Feb; 7(7):8389-98. PubMed ID: 26701731
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum chemokine (C-C motif) ligand 2 levels and prognosis in colorectal cancer.
Szczepanik AM; Siedlar M; Szura M; Kibil W; Brzuszkiewicz K; Brandt P; Kulig J
Pol Arch Med Wewn; 2015; 125(6):443-51. PubMed ID: 26020569
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of urinary and serum level of chemokine (C-C motif) ligand 2 as a potential biomarker in canine urothelial tumours.
Shimizu N; Hamaide A; Dourcy M; Noël S; Clercx C; Teske E
Vet Comp Oncol; 2019 Mar; 17(1):11-20. PubMed ID: 30588734
[TBL] [Abstract][Full Text] [Related]
6. Elevated Serum Levels of Monocyte Chemotactic Protein-1/Chemokine C-C Motif Ligand 2 are Linked to Disease Severity in Patients with Fibromyalgia Syndrome.
Zhao YC; Hu T; Chen Y; Du KT
Balkan Med J; 2019 Oct; 36(6):331-336. PubMed ID: 31486327
[TBL] [Abstract][Full Text] [Related]
7. Monocyte-Induced Prostate Cancer Cell Invasion is Mediated by Chemokine ligand 2 and Nuclear Factor-κB Activity.
Lindholm PF; Sivapurapu N; Jovanovic B; Kajdacsy-Balla A
J Clin Cell Immunol; 2015 Apr; 6(2):. PubMed ID: 26317041
[TBL] [Abstract][Full Text] [Related]
8. Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14
Spary LK; Salimu J; Webber JP; Clayton A; Mason MD; Tabi Z
Oncoimmunology; 2014 Oct; 3(9):e955331. PubMed ID: 25941611
[TBL] [Abstract][Full Text] [Related]
9. CCL2 (C-C Motif Chemokine Ligand 2) Biomarker Responses in Central Versus Peripheral Compartments After Focal Cerebral Ischemia.
Shi J; Li W; Zhang F; Park JH; An H; Guo S; Duan Y; Wu D; Hayakawa K; Lo EH; Ji X
Stroke; 2021 Nov; 52(11):3670-3679. PubMed ID: 34587791
[TBL] [Abstract][Full Text] [Related]
10. Urinary chemokine (C-C motif) ligand 2 (monocyte chemotactic protein-1) as a tubular injury marker for early detection of cisplatin-induced nephrotoxicity.
Nishihara K; Masuda S; Shinke H; Ozawa A; Ichimura T; Yonezawa A; Nakagawa S; Inui K; Bonventre JV; Matsubara K
Biochem Pharmacol; 2013 Feb; 85(4):570-82. PubMed ID: 23291264
[TBL] [Abstract][Full Text] [Related]
11. CCL2 Chemokine as a Potential Biomarker for Prostate Cancer: A Pilot Study.
Tsaur I; Noack A; Makarevic J; Oppermann E; Waaga-Gasser AM; Gasser M; Borgmann H; Huesch T; Gust KM; Reiter M; Schilling D; Bartsch G; Haferkamp A; Blaheta RA
Cancer Res Treat; 2015 Apr; 47(2):306-12. PubMed ID: 25483747
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal Fluid Chemokine (C-C Motif) Ligand 2 Is an Early-Response Biomarker for Blast-Overpressure-Wave-Induced Neurotrauma in Rats.
Wang Y; Wei Y; Oguntayo S; Wilder D; Tong L; Su Y; Gist I; Arun P; Long JB
J Neurotrauma; 2017 Feb; 34(4):952-962. PubMed ID: 27487732
[TBL] [Abstract][Full Text] [Related]
13. Postoperative elevation in the plasma CCL2 level is a predictive biomarker of colorectal cancer recurrence.
Fukunaga M; Mimori K; Masuda T; Hu Q; Yamada K; Mori M
Surg Today; 2021 Oct; 51(10):1671-1681. PubMed ID: 33797637
[TBL] [Abstract][Full Text] [Related]
14. The role of chemokine C-C motif ligand 2 genotype and cerebrospinal fluid chemokine C-C motif ligand 2 in neurocognition among HIV-infected patients.
Thames AD; Briones MS; Magpantay LI; Martinez-Maza O; Singer EJ; Hinkin CH; Morgello S; Gelman BB; Moore DJ; Heizerling K; Levine AJ
AIDS; 2015 Jul; 29(12):1483-91. PubMed ID: 26244388
[TBL] [Abstract][Full Text] [Related]
15. Changes in plasma chemokine C-C motif ligand 2 levels during treatment with eicosapentaenoic acid predict outcome in patients undergoing surgery for colorectal cancer liver metastasis.
Volpato M; Perry SL; Marston G; Ingram N; Cockbain AJ; Burghel H; Mann J; Lowes D; Wilson E; Droop A; Randerson-Moor J; Coletta PL; Hull MA
Oncotarget; 2016 May; 7(19):28139-50. PubMed ID: 27058904
[TBL] [Abstract][Full Text] [Related]
16. Chemokine (C-C motif) ligand 2 and chemokine (C-C motif) ligand 7 in angle-closure glaucoma.
Gao X; Huang W; Zhang X; Du S; Wang J; Wang W; Zhou M; Chen S; Li X; Jonas JB
Acta Ophthalmol; 2016 May; 94(3):e220-4. PubMed ID: 25726969
[TBL] [Abstract][Full Text] [Related]
17. CCL2 produced by CD68+/CD163+ macrophages as a promising clinical biomarker of microscopic polyangiitis-interstitial lung disease.
Matsuda S; Kotani T; Kuwabara H; Suzuka T; Kiboshi T; Fukui K; Ishida T; Fujiki Y; Shiba H; Hata K; Shoda T; Hirose Y; Takeuchi T
Rheumatology (Oxford); 2021 Oct; 60(10):4643-4653. PubMed ID: 33493350
[TBL] [Abstract][Full Text] [Related]
18. Understanding the role of circulating chemokine (C-C motif) ligand 2 in patients with chronic ischemia threatening the lower extremities.
Rull A; Hernandez-Aguilera A; Fibla M; Sepulveda J; Rodríguez-Gallego E; Riera-Borrull M; Sirvent JJ; Martín-Paredero V; Menendez JA; Camps J; Joven J
Vasc Med; 2014 Dec; 19(6):442-51. PubMed ID: 25336430
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
Xue M; Guo Z; Cai C; Sun B; Wang H
Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
[TBL] [Abstract][Full Text] [Related]
20. Association of HIV viral load with monocyte chemoattractant protein-1 and atherosclerosis burden measured by magnetic resonance imaging.
Floris-Moore M; Fayad ZA; Berman JW; Mani V; Schoenbaum EE; Klein RS; Weinshelbaum KB; Fuster V; Howard AA; Lo Y; Schecter AD
AIDS; 2009 May; 23(8):941-9. PubMed ID: 19318907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
